Day: November 1, 2024

VANCOUVER, BC, Nov. 01, 2024 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV)(FOBIF: OTCQB) (the “Company” or “Fobi”), an industry leader in harnessing AI and data intelligence to enable digital transformation, acknowledges the recent issuance of a Cease Trade Order by regulatory authorities due to the non-filing of the annual 2024 financial documents. “We want to assure our shareholders, stakeholders, and the public that the Company is fully committed to resolving this situation and completing the financial audit as quickly as possible. Rob Anson, CEO of Fobi AI, states: “The delay in completing our 2024 annual filing is certainly disappointing. Unlike last year, we chose not to proactively file for an MCTO because we were confident in meeting our filing deadline. I want to assure you that our team and auditors are fully committed...

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology’s evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accepted for a poster spotlight presentation at the San Antonio...

OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) — OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from December 10–13, 2024. Poster presentation details:Poster Title: Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant...

NAPLES, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) — Beasley Broadcast Group, Inc. (Nasdaq: BBGI) (“Beasley” or the “Company”), a multi-platform media company, announced today that it will report its 2024 third quarter financial results before the market opens on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 11:30 a.m. ET that morning to review the results. To access the conference call, interested parties may dial 877-407-4018 or 201-689-8471, conference ID  13749767 (domestic and international callers). Participants can also listen to a live webcast of the call at the Company’s website at www.bbgi.com. Please allow 15 minutes to register and download and install any necessary software. Following its completion, a replay of the webcast can be accessed for five days on the Company’s website, www.bbgi.com. Questions...

CALGARY, Alberta, Nov. 01, 2024 (GLOBE NEWSWIRE) — South Bow Corp. (TSX & NYSE: SOBO) has received an unsolicited “mini-tender” offer from TRC Capital Investment Corp. (TRC Capital) to purchase up to 3 million South Bow common shares, or approximately 1.4% of South Bow’s outstanding common shares, at a below-market price of C$31.95. South Bow does not endorse TRC Capital’s unsolicited offer, has no affiliation with TRC Capital or its offer, and does not recommend or endorse this unsolicited mini-tender offer. South Bow cautions shareholders that the mini-tender offer has been made at a below-market price for the South Bow common shares. TRC Capital’s unsolicited offer price of C$31.95 per share represents a discount of 4.6% to the closing price of the South Bow common shares on the Toronto Stock Exchange...

TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) — Nubian Resources Ltd. (TSX-V: NBR | OTCQB: NBRFF) (“Nubian” or the “Company”) announces that it has granted an aggregate of 2,550,000 options to purchase common shares of the Company exercisable at a price of $0.10 per share for a period of three years, to directors, officers and consultants of the Company. ABOUT NUBIAN Nubian Resources Ltd. is a publicly traded precious metals exploration company listed on the TSX Venture Exchange. The Company is managed by a team of experienced mining and geological professionals. Nubian’s main project is the Esquilache Silver Project, an advanced stage silver project located in Peru’s southern Cordillera Silver Belt. Nubian also holds gold projects in Australia (central Victoria and Tasmania) and Nevada through its significant stake in Athena Gold Corporation,...

HOUSTON, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”) today announces that Paul L. Kessler has resigned as a member of Prairie’s Board of Directors, effective October 30, 2024. Mr. Kessler, citing time constraints posed by scheduling and professional commitments, played a key role in structuring the Company and creating value for the resulting entity. “We are saddened to lose Paul as a valued member of Prairie’s Board of Directors” stated Edward Kovalik, Chairman and CEO of the Company. “While we appreciate that Paul has numerous outside commitments, his unwavering commitment, insight and dedication to the Company will be missed.” Mr. Kessler continued, “It has been my pleasure to serve alongside you through the structuring phase of the Company. I offer my best wishes...